Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 6/20 | 0.37 |
| ▸ | TEK | Q02763 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138344 | 0.90 | MTOR (0.41) | P2RY14MTORCSNK1DCSNK1EKDM4E | |
| SCHEMBL2133800 | 0.89 | NPC1 (0.39) | DDR2P2RY14MTORKDM4ERAF1 | |
| SCHEMBL2136538 | 0.86 | NPC1 (0.36) | P2RY14MTORABL1KDM4EALDH1A1 | |
| SCHEMBL2134868 | 0.86 | NPC1 (0.38) | P2RY14MTORABL1KDM4EALDH1A1 | |
| SCHEMBL2135220 | 0.85 | NPC1 (0.39) | CSNK1DCSNK1EABL1KDM4EALDH1A1 | |
| SCHEMBL2133207 | 0.84 | NPC1 (0.38) | ABL1KDM4EALDH1A1 | |
| SCHEMBL2135031 | 0.83 | NPC1 (0.47) | ABL1KDM4EALDH1A1 | |
| SCHEMBL2135790 | 0.83 | PDE2A (0.37) | ABL1KDM4EALDH1A1 | |
| SCHEMBL2136484 | 0.83 | NPC1 (0.42) | ABL1KDM4EALDH1A1 | |
| SCHEMBL2133828 | 0.82 | NPC1 (0.40) | DDR2P2RY14KDRTEKMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | claimed |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | DDR2 3491/4885P2RY14 1323/4885KDR 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.